Literature DB >> 28391043

The effect of VPA on bone: From clinical studies to cell cultures-The molecular mechanisms revisited.

Dimitris A Pitetzis1, Martha G Spilioti1, John G Yovos2, Maria P Yavropoulou3.   

Abstract

PURPOSE: Valproic acid (VPA) is a broad-spectrum antiepileptic drug, which is widely used as a first line treatment for idiopathic and symptomatic generalized epilepsy, as well as in non-epileptic psychiatric disorders in adult and pediatric patients. Although valproic acid is considered to be a generally well-tolerated drug, numerous studies have shown an increased bone loss and fracture risk in patients treated with VPA. The purpose of this review is to outline recent findings on VPA molecular mechanisms and their action on bone metabolism.
METHODS: Unrestricted electronic search of medical databases, complemented by additional manual searches, was performed by August 2016. RESULTS/
CONCLUSION: The main effects of VPA on bone metabolism involve a decrease in osteoblast proliferation, changes in collagen synthesis as well as an induction of vitamin D catabolism. Apart from these direct actions of VPA in bone, indirect effects affecting other endocrine organs also contribute to VPA-induced bone loss.
Copyright © 2017 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bone metabolism; HDAC; Molecular mechanisms; Valproic acid; Vitamin D

Mesh:

Substances:

Year:  2017        PMID: 28391043     DOI: 10.1016/j.seizure.2017.03.013

Source DB:  PubMed          Journal:  Seizure        ISSN: 1059-1311            Impact factor:   3.184


  3 in total

1.  Fragility fractures and reversible osteopaenia due to chronic hyponatraemia in an adolescent male.

Authors:  Mital Patel; Juan Carlos Ayus; Michael L Moritz
Journal:  BMJ Case Rep       Date:  2019-07-27

Review 2.  Bone Health in Childhood Chronic Disease.

Authors:  David R Weber
Journal:  Endocrinol Metab Clin North Am       Date:  2020-10-13       Impact factor: 4.741

3.  Bone Mineral Density Loss in People With Epilepsy Taking Valproate as a Monotherapy: A Systematic Review and Meta-Analysis.

Authors:  Rui Zhong; Qingling Chen; Xinyue Zhang; Mengmeng Li; Jianmin Liang; Weihong Lin
Journal:  Front Neurol       Date:  2019-11-08       Impact factor: 4.003

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.